Schwartzberg_edit.qxp 22/10/08 12:50 pm Page 29
Management of Chemotherapy-induced Neutropoenia
Conclusion and subsequent cycles with myelosuppressive chemotherapy markedly
CIN remains the most common serious toxicity of current chemotherapeutic reduces the risk of FN and is uniformly recommended by current guidelines.
regimens for cancer and is frequently responsible for dose reductions and Pegfilgrastim, a long-acting form of G-CSF given once per cycle, is more
delays, which may compromise outcome. Febrile neutropoenia continues to convenient for the patient and the healthcare system and is at least as or
have serious sequelae in a fraction of patients receiving myelosuppressive more effective as daily dosing of G-CSF. ■
treatment. Both chemotherapy regimens and patient- and disease-specific
factors should be taken into account when considering the risk of Publication of this article was supported by an unrestricted grant from
developing CIN. The use of growth factor support prophylactically in first Amgen (Europe) GmbH, Zug, Switzerland.
1. Bodey GP, Buckley M, Sathe YS, Freireich EJ, Quantitative elderly patients with aggressive non-Hodgkin’s lymphoma, 36. Younes A, Fayad L, Romaguera J, et al., Safety and efficacy of
relationships between circulating leukocytes and infection in J Clin Oncol, 2003;21(16):3041–50. once-per-cycle pegfilgrastim in support of ABVD chemotherapy in
patients with acute leukemia, Ann Intern Med, 1966;64(2):328–40. 19. Holmes FA, O’Shaughnessy JA, Vukelja S, et al., Blinded, patients with Hodgkin lymphoma, Eur J Cancer, 2006;42(17):
2. Kuderer NM, Dale DC, Crawford J, et al., Mortality, morbidity, and randomized, multicenter study to evaluate single administration 2976–81.
cost associated with febrile neutropenia in adult cancer patients, pegfilgrastim once per cycle versus daily filgrastim as an adjunct to 37. Kubista E, Glaspy J, Holmes F, et al.; Pegfilgrastim Study Group,
Cancer, 2006;106(10):2258–66. chemotherapy in patients with high-risk stage II or stage III/IV Bone pain associated with once-per-cycle pegfilgrastim is similar
3. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al., breast cancer, J Clin Oncol, 2002;20(3):727–31. to daily filgrastim in patients with breast cancer, Clin Breast
Prognostic factors influencing mortality in cancer patients with 20. Green MD, Keolbl H, Baselga J, et al., A randomized double-blind Cancer, 2003;3(6):391–8.
neutropenia and bacteremia, Eur J Clin Microbiol Infect Dis, multicenter phase III study of fixed-dose single-administration 38. Bucaneve G, Micozzi A, Menichetti F, et al., Levofloxaxcin to
1999;18(8):539–44. pegfilgrastim versus daily filgrastim in patients receiving prevent bacterial infection in patients in cancer and neutropenia, N
4. Klastersky J, Paesmans M, Rubenstein EB, et al., The Multinational myelosuppressive chemotherapy, Ann Oncol, 2003;14(1):29–35. Engl J Med, 2005;353:977–87.
Association for Supportive Care in Cancer risk index: A 21. Siena S, Piccart MJ, Holmes FA, et al., A combined analysis of two 39. Gafter-Gvili A, Fraser A, Paul M, et al., Meta-analysis: antibiotic
multinational scoring system for identifying low-risk febrile pivotal randomized trials of a single dose of pegfilgrastim per prophylaxis reduces mortality in neutropenic patients, Ann Int
neutropenic cancer patients, J Clin Oncol, 2000;18(16):3038–51. chemotherapy cycle and daily Filgrastim in patients with stage II- Med, 2005;142:979–95.
5. Uys A, Rapoport BL, Anderson R, Febrile neutropenia: a IV breast cancer, Oncol Rep, 2003;10(3):715–24. 40. Martin M, Pienkowski T, Mackey J, et al., Adjuvant docetaxel for
prospective study to validate the Multinational Association of 22. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al., First and node-positive breast cancer, N Engl J Med, 2005;352:2302–13.
Supportive Care of Cancer (MASCC) risk-index score, Support Care subsequent cycle use of pegfilgrastim prevents febrile neutropenia 41. Martin M, Lluch A, Segui MA, et al., Toxicity and health-related
Cancer, 2004;12(8):555–60. in patients with breast cancer: a multicenter, double-blind, quality of life in breast cancer patients receiving adjuvant
6. Klastersky J, Paesmans M, Georgala A, et al., Outpatient oral placebo-controlled phase III study, J Clin Oncol, 2005;23(6): docetaxel, doxorubicin, cyclophosphamide (fAC) or 5-fluorouracil,
antibiotics for febrile neutropenia cancer patients using a score 1178–84. doxorubicin and cyclophosphamide (FAC): impact of adding
predictive for complications, J Clin Oncol, 2006;24(25):4129–34. 23. Pinto L, Liu Z, Doan Q, et al., Comparison of pegfilgrastim with primary prophylactic granulocyte-colony stimulating factor to the
7. Cherif H, Johansson E, Bjorkholm M, Kalin M, The feasibility of filgrastim on febrile neutropenia, grade IV neutropenia and bone TAC regimen, Ann Oncol, 2006;17:1205–12.
early hospital discharge with oral antimicrobial therapy in low risk pain: a meta-analysis of randomized controlled trials, Curr Med 42. von Minckwitz G, Kummel S, du Bois A, et al., Pegfilgrastim +
patients with febrile neutropenia following chemotherapy for Rsch Opin, 2007;9(23):2283–95. ciprofloxacin for primary prophylaxis with TAC (docetaxel/
hematologic malignancies, Haematologica, 2006;91(2):215–22. 24. Lyman GH, Lyman CH, Agboola O, Risk Models for predicting doxorubicin/cyclophosphamide) chemotherapy for breast cancer,
8. Uys A, Rapoport BL, Fickl H, et al., Prediction of outcome in chemotherapy-induced neutropenia, The Oncologist, 2005;10: Results from the GEPARTRIO study, Ann Oncol, 2008;19;292–8.
cancer patients with febrile neutropenia: comparison of the 427–37. 43. Smith TJ, Khatcheressian J, Lyman GH, et al., 2006 update of
Multinational Association of Supportive Care in Cancer risk-index 25. Elting LS, Rubenstein EB, Rolston KV, Bodey GP, Outcomes of recommendations for the use of white blood cell growth factors:
score with procalcitonin, C-reactive protein, serum amyloid A, and bacteremia in patients with cancer and neutropenia: observations an evidence-based clinical practice guideline, J Clin Oncol,
interleukins-1beta, -6, -8, and -10, Eur J Cancer Care (Engl), from two decades of epidemiological and clinical trials, Clin Infect 2006;24(19):3187–3205.
2007;16(6):475–83. Dis, 1997;25(2):S1–S75. 44. Crawford J, Allthaus B, Armitage J, et al., Myeloid growth factors.
9. Klastersky J, Paesmans M, Risk-adapted strategy for the 26. Lyman GH, Morrison VA, Dale DC, et al., Risk of febrile Clinical practice guidelines in oncology, J Natl Compr Canc Netw,
management of febrile neutropenia in cancer patients, Support neutropenia among patients with intermediate-grade non- 2007;5(2):117.
Care Cancer, 2007;15(5):477–82. Hodgkin’s lymphoma receiving CHOP chemotherapy, Leuk 45. Aapro MS, Cameron DA, Pettengell R, et al., EORTC guidelines for
10. Weycker D, Malin J, Edelsberg J, et al., Cost of neutropenic Lymphoma, 2003;44(12):2069–76. the use of granulocyte-colony stimulating factor to reduce the
complications of chemotherapy, Ann Oncol, 2008;19(3):454–60. 27. Crawford J, Dale DC, Kuderer NM, et al., Risk and timing of incidence of chemotherapy-induced febrile neutropenia in adult
11. Bonadonna G, Valagussa P, Moliterni A, et al., Adjuvant neutropenic events in adult cancer patients receiving patients with lymphomas and solid tumours, Eur J Cancer,
cyclophosphamide, methotrexate, and fluorouracil in node-positive chemotherapy: the results of a prospective nationwide study of 2006;42(15):2433–53.
breast cancer: the results of 20 years of follow-up, N Engl J Med, oncology practice, JNCCN, 2008;6:109–118. 46. Balducci L, Al-Halawanitl, Charu V, et al., Elderly cancer patients
1995;332(14):901–6. 28. Kuderer NM, Dale DC, Crawford J, Lyman GH, Impact of primary receiving chemotherapy benefit from first-cycle pegfilgrastim,
12. Budman DR, Berry DA, Cirrincione CT, et al., Dose and dose prophylaxis with granulocyte colony-stimulating factor on febrile Oncologist, 2007;12(12)1416–24.
intensity as determinants of outcome in the adjuvant treatment of neutropenia and mortality in adult cancer patients receiving 47. Kaufman PA, Paroly W, Rinaldi D, et al., Randomized double-blind
breast cancer. The Cancer and Leukemia Group B, J Natl Cancer chemotherapy: a systematic review, J Clin Oncol, phase 2 study evaluating same-day vs. next-day administration of
Inst, 1998;90:1205–11. 2007;(21):3158–67. pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide
13. Lyman GH, Dale DC, Crawford J, Incidence and predictors of low 29. Hackshaw A, Sweetenham J, Knight A, Are prophylactic (TAC) in women with early stage and advanced breast cancer,
dose-intensity in adjuvant breast cancer chemotherapy: a haematopoietic growth factors of value in the management of Breast Cancer Res Treat, 2004;88:559 (abstract 1054).
nationwide study of community practices, J Clin Oncol, patients with aggressive non-Hodgkin’s lymphoma?, Br J Cancer, 48. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH, Economic
2003;21(24):4524–31. 2004;90(7):1302–5. analysis of prophylactic pegfilgrastim in adult cancer patients
14. Crawford J, Ozer H, Stroller R, et al., Reduction by granulocyte 30. Rivera E, Erder MH, Moore TD, et al., Targeted filgrastim support in receiving chemotherapy, Value Health, 2008;11(2):172–9.
colony-stimulating factor of fever and neutropenia induced by patients with early-stage breast carcinoma: toward the 49. Timmer-Bonte JN, Adang EM, et al., Cost-effectiveness of adding
chemotherapy in patients with small-cell lung cancer, N Engl J implementation of a risk model, Cancer, 2003;98(2):222–8. granulocyte colony-stimulating factor to primary prophylaxis with
Med, 1991;325(3):164–70. 31. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al., antibiotics in small cell lung cancer, J Clin Oncol, 2006;24(19):
15. Trillet-Lenoir V, Green J, Manegold C, et al., Recombinant Granulocyte colony-stimulating factor in the treatment of high-risk 2991–7.
granulocyte colony stimulating factor reduces the infectious febrile neutropenia: a multicenter randomized trial, J Natl Cancer 50. Numnum TM, Kimball KJ, Rocconi RP, et al., Pegfilgrastim for the
complications of cytotoxic chemotherapy, Eur J Cancer, Inst, 2001;93:31–8. prevention of febrile neutropenia in patients with epithelial
1993;29A:319–24. 32. Clark OA, Lyman GH, Castro AA, et al., Colony-stimulating factors ovarian carcinoma-a cost-effectiveness analysis, Int J Gynecol
16. Bui BN, Chevallier B, Chevreau C, et al., Efficacy of lenograstim on for chemotherapy-induced febrile neutropenia: a meta-analysis of Cancer, 2007;17(5):1019–24.
hematologic tolerance to MAID chemotherapy in patients with randomized controlled trials, J Clin Oncol, 2005;(23):4198–4214. 51. Calhoun EA, Schumock GT, McKoy JM, et al., Granulocyte colony-
advanced soft tissue sarcoma and consequences on treatment 33. Andre N, Kababri ME, Bertrand P, et al. Safety and efficacy of stimulating factor for chemotherapy-induced neutropenia in
dose-intensity, J Clin Oncol, 1995;13(10):2629–36. pegfilgrastim in children with cancer receiving myelosuppressive patients with small cell lung cancer: the 40% rule revisited,
17. Fossa SD, Kaye SB, Mead GM, et al., Filgrastim during chemotherapy, Anticancer Drugs, 2007;18(3):277–81. Pharmacoeconomics, 2005;23(8):767–75.
combination chemotherapy of patients with poor-prognosis 34. Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic 52. Wolowacz SE, Cameron DA, Tate HC, Bagust A, Docetaxel in
metastatic germ cell malignancy. European Organization for filgrastim schedules on hematologic toxicity in early breast cancer combination with doxorubicin and cyclophosphamide as adjuvant
Research and Treatment of Cancer, Genito-Urinary Group, and the patients treated with epirubicin and cyclophosphamide, J Clin treatment for early node-positive breast cancer: a cost-effectiveness
Medical Research Council Testicular Cancer Working Party, Oncol, 2005;23(28):6908–18. and cost-utility analysis, J Clin Oncol, 2008;26(6):925–33.
Cambridge, United Kingdom, J Clin Oncol, 1998;16(2):716–24. 35. Weycker D, Hackett J, Edelsberg JS, et al., Are shorter courses of 53. Timmer-Bonte JN, Adang EM, Termeer E, et al., Modeling the cost
18. Doorduijin JK, van der Holt B, van Imhoff GW, et al., CHOP filgrastim prophylaxis associated with increased risk of effectiveness of secondary febrile neutropenia prophylaxis during
compared with CHOP plus granulocyte colony-stimulating factor in hospitalization?, Ann Pharmacother, 2006;40(3):402–7. standard-dose chemotherapy, J Clin Oncol, 2008;26(2):290–96.
EUROPEAN ONCOLOGY 29
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99